BioCryst Pharmaceuticals announced a cash-and-stock acquisition of Astria Therapeutics that values Astria at about $700 million. The deal transfers navenibart, a long-acting injectable plasma kallikrein inhibitor in late‑stage development, into BioCryst’s hereditary angioedema (HAE) franchise. BioCryst expects the candidate to complement its oral Orladeyo and to shore up its preventive therapy offerings while Phase 3 data mature in 2027. Analysts framed the purchase as a strategically focused bolt-on that accelerates BioCryst’s shift to long‑duration HAE prophylaxis.